Valuation

DVADaVita

StockNYSEUnited StatesHealth careEU retail investors: available

−1.9% today · +53.0% over a year

10/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 98% of the instruments we score

Quality, Stability: among the best of its peers; priced lower than most peers. No dividend.

DaVita (DVA) valuation against sector peers: P/E 12.5 (sector median 30.1), EV/EBIT 10.3, free-cash-flow yield 11.3%, P/S 0.8.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricDVASector medianvs median
P/E12.530.1 · n=15059% below
P/B—3.9 · n=304—
P/S0.84.2 · n=29781% below
EV/EBIT10.325.8 · n=14060% below
Free-cash-flow yield11.3%1.4% · n=289681% above
Dividend yield0.00%0.00% · n=361—
Return on equity—−3.7% · n=306—
Return on invested capital17.9%0.5% · n=2763,271% above
Gross margin—62.4% · n=204—
Net debt / EBITDA3.621.30 · n=145179% above

Value factor: 89 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

LLYEli Lilly & Co48.132.9—1.5%0.6%7/10
JNJJohnson & Johnson39.87.9—3.2%2.0%8/10
ABBVAbbVie49.1—27.13.7%3.0%6/10
UNHUnitedHealth22.83.517.36.3%2.2%10/10
MRKMerck112.58.5—4.5%2.4%9/10
TMOThermo Fisher Scientific36.64.734.72.9%0.3%9/10
AMGNAmgen28.521.325.64.1%2.2%7/10
GILDGilead Sciences—15.9—6.6%1.9%5/10
ABTAbbott30.23.728.33.9%2.8%6/10
PFEPfizer42.41.9—6.9%7.2%1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Sep 2026 · filed 29 Oct 2026